Adverum Biotechnologies Appoints Andrew Ramelmeier, Ph.D. as Chief Technology Officer
21 Agosto 2023 - 10:05PM
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage
company that aims to establish gene therapy as a new standard of
care for highly prevalent ocular diseases, today announced that R.
Andrew “Andy” Ramelmeier, Ph.D., has joined Adverum as the
company’s chief technology officer. Dr. Ramelmeier will serve as a
member of Adverum’s executive committee and will lead Adverum’s
technology and operations organization, including process
development and assay development for Adverum’s investigational
gene therapy ixoberogene soroparvovec (Ixo-vec). Ixo-vec is
currently being evaluated in the Phase 2 LUNA trial as a potential
one-time intravitreal (IVT) injection for patients in the treatment
of neovascular or wet age-related macular degeneration (wet AMD).
“Andy’s deep experience across process and assay development and
scale up of CMC, including transitioning and expanding viral vector
gene therapy capabilities to global commercial scale and with the
SF9 technology platform, will be critically important as we
continue to execute on Ixo-vec’s clinical development and build out
our pipeline,” stated Peter Soparkar, chief operating officer of
Adverum Biotechnologies. “Ixo-vec has shown therapeutic aflibercept
levels and stabilized vision in patients with wet AMD with a single
IVT injection out to three years. With the Phase 2 LUNA trial fully
enrolled, our manufacturing focus is on scale up for our future
commercialization of Ixo-vec.”
“I am delighted to join Adverum to advance its proprietary
AAV.7m8 vector capsid to address highly prevalent ocular diseases,”
commented Dr. Ramelmeier. “Ixo-vec’s promising profile presents an
opportunity to provide access to a potential functional cure and to
reduce the treatment burden and cost for millions of patients with
wet AMD worldwide. I look forward to applying my gene therapy
manufacturing expertise to advance Ixo-vec towards pivotal trials
and global commercialization.”
Dr. Ramelmeier has more than 30 years of experience in the
development and manufacturing of biopharmaceuticals, including
monoclonal antibodies, vaccines, gene and cell therapy products and
therapeutic proteins. Most recently, Dr. Ramelmeier served as
executive vice president, head of technical operations at Sangamo
Therapeutics, where he was responsible for quality, process and
analytical development, manufacturing and supply chain of viral
vector and cell therapy pipeline products, as well as the oversight
of two internal GMP facilities and multiple contract manufacturing
organizations (CMOs) /contract research organizations (CROs) for
manufacturing and quality control (QC) activities. Prior to
Sangamo, Dr. Ramelmeier served as senior vice president, technical
operations at Portola Pharmaceuticals, responsible for the process
development, technology transfer, manufacturing, and supply chain
of small and large molecule pipeline products. Before that, Dr.
Ramelmeier held positions of increasing responsibility at several
companies, including BioMarin Pharmaceuticals, Johnson &
Johnson and Merck Research Laboratories. Dr. Ramelmeier
earned his B.E.S. in Chemical Engineering from Johns Hopkins
University and a Ph.D. in Chemical Engineering from University of
California, Berkeley. He conducted post-doctoral work at The
Institute of Enzyme Technology affiliated with the
Heinrich-Heine-University of Dusseldorf.
Inducement GrantOn August 21, 2023, the company
granted Dr. Ramelmeier a stock option to purchase 400,000 shares of
Adverum’s common stock pursuant to the inducement grant exception
under Nasdaq Rule 5635(c)(4), as an inducement that is material to
his entering into employment with Adverum. The option has a
per-share exercise price equal to the closing sales price of
Adverum’s common stock on the Nasdaq Stock Market on the grant
date, and will vest over four years, subject to his continued
service with Adverum.
About Adverum BiotechnologiesAdverum
Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that
aims to establish gene therapy as a new standard of care for highly
prevalent ocular diseases with the aspiration of developing
functional cures to restore vision and prevent blindness.
Leveraging the capabilities of its proprietary intravitreal (IVT)
platform, Adverum is developing durable, single-administration
therapies, designed to be delivered in physicians’ offices, to
eliminate the need for frequent ocular injections to treat these
diseases. Adverum is evaluating its novel gene therapy
candidate, ixoberogene soroparvovec (Ixo-vec, formerly
referred to as ADVM-022), as a one-time, IVT injection for patients
with neovascular or wet age-related macular degeneration.
Additionally, by overcoming the challenges associated with current
treatment paradigms for debilitating ocular diseases, Adverum
aspires to transform the standard of care, preserve vision, and
create a profound societal impact around the globe. For more
information, please visit www.adverum.com.
Forward-looking StatementsStatements contained
in this press release regarding events or results that may occur in
the future are “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995. Such
statements include but are not limited to statements regarding the
potential benefits of Ixo-vec in the treatment of wet AMD,
manufacturing scale up for future commercialization of Ixo-vec, and
the advancement of Adverum’s proprietary AAV.7m8 vector capsid.
Actual results could differ materially from those anticipated in
such forward-looking statements as a result of various risks and
uncertainties, including risks inherent to, without limitation:
Adverum’s novel technology, which makes it difficult to predict the
timing of commencement and completion of clinical trials;
regulatory uncertainties; enrollment uncertainties; the results of
early clinical trials not always being predictive of future
clinical trials and results; and the potential for future
complications or side effects in connection with use of Ixo-vec.
Additional risks and uncertainties facing Adverum are set forth
under the caption “Risk Factors” and elsewhere in Adverum’s
Securities and Exchange Commission (SEC) filings and reports,
including Adverum’s Quarterly Report on Form 10-Q for the quarter
ended June 30, 2023 filed with the SEC on August 10, 2023. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Adverum undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
Corporate, Investor and Media InquiriesAnand
ReddiVice President, Head of Corporate Strategy, External Affairs
and EngagementAdverum Biotechnologies, Inc.T:
650-649-1358E: areddi@adverum.com
Grafico Azioni Adverum Biotechnologies (NASDAQ:ADVM)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Adverum Biotechnologies (NASDAQ:ADVM)
Storico
Da Giu 2023 a Giu 2024